Amylyx announced a restructuring to focus the Company’s financial resources on upcoming clinical milestones. The Company will reduce its workforce by approximately 70% and decrease external financial commitments outside of its priority areas. With these changes, Amylyx expects to have cash runway into 2026, which will allow the organization to deliver on key upcoming milestones, including data readouts from HELIOS, ORION, and its planned trial of AMX0114 in ALS.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
